Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance [exome-seq]

ABSTRACT: MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance [exome-seq]

PROVIDER: PRJNA862165 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance

Project description:MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance

| PRJNA862161 | ENA

MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance [RNA-seq]

Project description:MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance [RNA-seq]

| PRJNA862159 | ENA

MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance [exome-seq]

Project description:Pre-clinical model to study tumor immune resistance are essential. To this end, we generated cell lines from tumors induced on BrafV600E Pten-/- mice. The cell lines have been characterized to evaluate the tumor growth in vivo and response to immunotherapies. In addition, we have also chaacterised the DNA expression profile of the cell lines.

2023-07-30 | GSE209729 | GEO

MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance [RNA-seq]

2023-07-30 | GSE209725 | GEO

MeVa2.1.dOVA is a novel immune-refractory cell line to study tumor immune resistance

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-07-30 | GSE209731 | GEO

Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Project description:To address the role of immune dysregulation in AML, we conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg IV on day 14 to examine whether programmed death-1 inhibition improves clinical responses in relapsed/refractory (R/R) AML. Overall responders could receive pembrolizumab maintenance up to two years. Among thirty-seven patients enrolled, the overall response rate, composite complete remission rate (CRc; primary endpoint), and median overall survival (OS) were 46%, 38% and 11.1 months, respectively. Patients with refractory/early relapse and those receiving treatment as first salvage had encouraging outcomes (median OS 13.2 and 11.3 months, respectively). Grade >3 immune-related adverse events were rare (14%) and self-limiting. Patients who achieved CRc had a higher frequency of progenitor exhausted CD8+ T-cells in the bone marrow prior to treatment and a non-significant increase in baseline T-cell diversity.

2021-09-09 | GSE183415 | GEO

Refractory Cancer (RC) Program

Project description:Refractory Cancer (RC) Program

| PRJNA663002 | ENA

Refractory Cancer (RC) Program

Project description:Refractory Cancer (RC) Program

| PRJNA663003 | ENA

Immune Profiles Study

Project description:Immune Profiles Study

| PRJNA861058 | ENA

Immune Profiles Study

Project description:Immune Profiles Study